Lung Ambition Alliance reveals plans to double lung cancer survival
Category: #health  By Pankaj Singh  Date: 2019-09-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lung Ambition Alliance reveals plans to double lung cancer survival
  • New program will be launched to help local initiatives run by patient organizations that contain the capability to further transform patient care.
     
  • The Lung Ambition Alliance has built an interactive booth where applicants will understand integrated quality care in lung cancer is.

The four members of Lung Ambition Alliance, Guardant Health, AstraZeneca, International Association for the Study of Lung Cancer (IASLC) and the Global Lung Cancer Coalition (GLCC) reportedly unveiled several novel initiatives to support their aim of increasing 5-year survival before 2025 at the IASLC World Conference on Lung Cancer.

President at the IASLC, Giorgio Scagliotti stated that the association has made great progress in a mere two months after the announcement of founding the Lung Ambition Alliance. New initiatives of Alliance, such as those in Lung Cancer Care (ILC2), exemplify association’s shared goal to work with the global community and promote ambitious in-country solutions which potentially would enhance lung cancer patient survival rates and also transform patient care.

ILC2 program is appealing enrolled patient organizations that focus on lung cancer, across the globe, to submit the proposals that have the capability to enhance survival into their home countries and transform patient care.

The program is created in identification of the high variation in the management of lung cancer across the globe, and very limited local obstacles to quality care that should be considered while developing solutions convenient to patients to address them.

The Lung Ambition Alliance has built an interactive booth where participants will understand integrated quality care in lung cancer is, while getting access to important resources of quality care along the way. Moreover, participants will also get a chance to provide feedback on this experience with this patient journey.

The Lung Ambition Alliance would officially accept grant proposals in November 2019 and would examine and then select those proposals which have fulfilled the funding criteria.

 

Source credit: https://www.globenewswire.com/news-release/2019/09/07/1912428/0/en/Lung-Ambition-Alliance-unveils-new-initiatives-to-address-lung-cancer-survival-at-the-World-Conference-on-Lung-Cancer.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...